GW high on pipeline of cannabis extracts
This article was originally published in Scrip
Executive Summary
GW Pharma has enjoyed recent success with its cannabinoid extract product Sativex (nabiximols), which is now approved in the UK and Spain as an add-on therapy for spasticity in multiple sclerosis, making it the first authorised cannabis-derived drug The UK company's managing director, Justin Gover, and director of R&D, Dr Stephen Wright, sat down with Scrip to talk about the buzz surrounding Sativex and what's next for its pipeline of cannabinoids.